Tacrolimus FK-506 followed by limiting the recruitment of female

Controlled trial The randomized, 6 nebivolol administration reduces the combined endpoint of mortality T and kardiovaskul Re hospitalization for Older patients with CHF, independent Ngig of their left ventricular Ren ejection fraction. In addition, a subgroup analysis of patients ENR Strips in the test has demonstrated a reduction in mortality observed nebivolol t Similar to other beta-blockers. Only two studies compared the effects of nebivolol and carvedilol in patients with CHF and the results were not conclusive on their comparative effects on left ventricular that Linear function and functional capacity.17, 18 However, pr Both studies, a trend in favor of carvedilol sentierten. The main objective of this study was to evaluate the effects of long-term treatment with nebivolol compared with carvedilol on LVEF in patients with hypertension to compare stable heart failure. We tested the hypothesis that carvedilol improves LVEF in a green Eren Ausma That nebivolol. The secondary Re aim of this study was to evaluate the effect of two beta-blockers on the k Rperliche load and clinical outcome. Methods The study was conducted as a randomized, prospective, parallel group controlled EAA active open-label, single-blind study. The study population included 160 patients with hypertension and a new diagnosis of heart failure. The patients were enrolled in the study if they had an LVEF! 40% New York Heart Association functional class I, II or III, and stability T without clinical heart failure hospitalization in the past 3 months. Patients were excluded if they had a history of asthma or severe chronic obstructive pulmonary disease, severe liver or kidney disease, heart-cons-indication for beta blockers as second or third degree heart block without pacemaker degree Standing heart, sick sinus syndrome, Heart rate! 60 key GE / min, systolic blood pressure! 90 mm Hg or Tacrolimus FK-506 concomitant treatment with other beta-blockers.
Studies of patient recruitment and randomization. Each participating patients affected clinicians to carvedilol or alternately with a list of ready-nebivolol. Clinicians reported w Hnen chentlichen figures vers. Hrleisten In an attempt to one Similar number of male pattern and female patients on weight, Was initially Highest on the registration of the male patients, followed by limiting the recruitment of female patients. Baseline visit. at the beginning of the study, the criteria for inclusion and exclusion evaluated and informed consent was signed. Eligible patients were randomized to either carvedilol or nebivolol and the first dose of the drug delivered. Echocardiography and testing of 6-minute walk were performed. Until the titration phase. Patients were given by w Chentliche visits w During the titration was followed up phase. For nebivolol, the starting dose was 1.25 mg once a day. If tolerated, it was ht to 2.5 mg once-t Possible increased until the end of week 1, 5 mg once t Resembled mg at week 2 and 10 t again Possible for 4 weeks. Carvedilol for anf Ngliche dose was half a tablet of 3.125 mg twice t Possible. If tolerated, but had to 3.125 mg twice a day until the end of Week 1 ht erh, 6.25 mg two times t Possible for 2 weeks, 12.5 mg twice a week 4 and 25 mg 6 times a week. If the side effects due to study medication occurred, titration was galvanized Siege, the dose was reduced or the drug was temporarily interrupted. Maintenance phase. On the realization of technical assistance.